Loading
A phase 2 trial of Serplulimab in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC is a phase 2 interventional study registered as NCT07269782 by Shanghai Henlius Biotech, with 60 participants planned, started 2026-01-20 and due to reach its primary completion in 2026-07-10. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2, Serplulimab. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.